Case Report: Long-term response to camrelizumab in PD-L1-negative/MSS advanced carcinoma ex pleomorphic adenoma of the palate
Year: 2026
Type: article
Study design: Case Report
Abstract: Carcinoma ex pleomorphic adenoma (CEPA) is an uncommon malignant salivary gland tumor arising from a preexisting pleomorphic adenoma and constitutes roughly 3.6% of all salivary gland neoplasms. We present a 67-year-old female patient diagnosed with CEPA in the palatal region, who received surgical excision followed by postoperative radiotherapy. Local tumor relapse in the palate was detected at the 4-year follow-up. Radical radiotherapy was administered concurrently with cisplatin monotherapy. Nevertheless, no significant tumor shrinkage was observed after radical chemoradiotherapy. The treatment regimen was subsequently modified to maintenance monotherapy with camrelizumab. The palatal mass showed continuous regression, and the patient remained clinically stable with ongoing long-term multidisciplinary surveillance. Camrelizumab was initiated on August 2, 2021, and the patient remained progression-free at the last follow-up in March 2025, corresponding to a progression-free survival of approximately 43 months. Despite programmed death ligand 1 (PD-L1) negativity (0% tumor cell staining) and microsatellite-stable (MSS) phenotype, the patient achieved durable remission. To our knowledge, this case is among the earliest reports confirming the clinical efficacy of immune checkpoint inhibitors (ICIs) in recurrent CEPA of the palate. Our findings suggest that ICIs can serve as a feasible systemic alternative option for patients with postoperative recurrence of palatal CEPA.
Source: Frontiers in Oncology
Authors: Qinyan Jiang, Jie Wang
Institution: Dalian Municipal Central Hospital
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225887225
